Rj. Stephens et al., Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise, BR J CANC, 79(3-4), 1999, pp. 538-544
The assessment of symptom palliation is an essential component of many trea
tment comparisons in clinical trials, yet an extensive literature search re
vealed no consensus as to its precise definition, which could embrace relie
f of symptoms, time to their onset, duration, degree, as well as symptom co
ntrol and prevention. in an attempt to assess the importance of these aspec
ts and to compare different methods of analysis, we used one symptom (cough
) from a patient self-assessment questionnaire (the Rotterdam Symptom Check
list) in a large (>300 patient) multicentre randomized clinical trial (cond
ucted by the Medical Research Council lung Cancer Working Party) of palliat
ive chemotherapy in small-cell lung cancer. The regimens compared were a tw
o-drug regimen (2D) and a four-drug regimen (4D). No differences were seen
between the regimens in time of onset of palliative or its duration. The de
gree of palliation was strongly related to the initial severity: 90% of the
patients with moderate or severe cough at baseline reported improvement, c
ompared with only 53% of those with mild cough. Analyses using different la
ndmark time points gave conflicting results: the 4D regimen was superior at
1 month and at 3 months, whereas at 2 months the 2D regimen appeared super
ior. When improvement at any time up to 3 months was considered, the 4D reg
imen showed a significant benefit (4D 79%, 2D 60%,, P= 0.02). These finding
s emphasize the need for caution in interpreting results, and the importanc
e of working towards a standard definition of symptom palliation. The curre
nt lack of specified criteria makes analysis and interpretation of trial re
sults difficult, and comparison across trials impossible. A standard defini
tion of palliation for use in the analysis of clinical trials data is propo
sed, which takes into account aspects of onset, duration and degree of pall
iation, and symptom improvement, control and prevention.